US 11,850,213 B2
Ophthalmic compositions of rifamycins and uses thereof
Hiroaki Serizawa, Palo Alto, CA (US)
Assigned to AMD THERAPEUTICS LLC, Middletown, DE (US)
Filed by AMD THERAPEUTICS LLC, Middletown, DE (US)
Filed on Nov. 13, 2020, as Appl. No. 17/098,272.
Application 17/098,272 is a continuation of application No. 15/327,951, abandoned, previously published as PCT/US2015/041196, filed on Jul. 20, 2015.
Claims priority of provisional application 62/174,884, filed on Jun. 12, 2015.
Claims priority of provisional application 62/136,222, filed on Mar. 20, 2015.
Claims priority of provisional application 62/027,189, filed on Jul. 21, 2014.
Prior Publication US 2021/0369726 A1, Dec. 2, 2021
Int. Cl. A61K 31/5383 (2006.01); A61K 31/496 (2006.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 31/435 (2006.01); A61K 47/02 (2006.01); A61K 47/10 (2017.01); A61K 47/14 (2017.01); A61K 47/26 (2006.01)
CPC A61K 31/5383 (2013.01) [A61K 9/0048 (2013.01); A61K 9/08 (2013.01); A61K 31/435 (2013.01); A61K 31/496 (2013.01); A61K 47/02 (2013.01); A61K 47/10 (2013.01); A61K 47/14 (2013.01); A61K 47/26 (2013.01)] 14 Claims
OG exemplary drawing
 
1. A method of treating an ocular disease, disorder or condition which results from ocular neovascularization comprising topically administering to a patient in need thereof a stable ophthalmic composition comprising about 0.01 wt % to 10 wt % of a solubilized rifamycin compound selected from rifampicin, rifabutin, rifapentine, rifaximin, or a pharmaceutically acceptable salt thereof, about 0.1 wt % to 50 wt % of a non-ionic surfactant, and a pH of about 2 to 12, wherein the composition does not comprise 0.1 wt % rifampicin in combination with 2 wt % polysorbate 80 (Tween 80)
wherein the pH is buffered with a citrate, a phosphate, a bicarbonate, a sodium salt, potassium, acetic acid, citric acid, lactic acid, phosphoric acid, hydrochloric acid, sodium hydroxide, sodium phosphate, sodium citrate, sodium acetate, sodium lactate, citrate/dextrose, sodium bicarbonate, ammonium chloride, or a combination thereof, wherein the composition is stable for at least one day.